Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
To extend the nationwide distribution network for the availability of its proprietary & award-winning HPod for corporates & doctors’ clinics, thereby strengthening India’s phygital wellness ecosystem
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
For over a decade, AstraZeneca and Plan India’s Young Health Program have been generating awareness and identifying sustainable solutions to influence the behaviour of youths against Non-Communicable Diseases
Danish National Genome Center partners with Lifebit to deliver nationwide personalised medicine
When a critical patient is en-route to the hospital and every second makes a difference, the 5G Connected ambulance acts as an extension of the emergency room
This facility will design & develop instruments, perform product reliability performance testing and verification
Beyond the technical leadership from F1, the collaboration will bring a specific focus on the people dimension of high performance
Subscribe To Our Newsletter & Stay Updated
